NBIX

Business Context and Reporting Period

Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1996
Business Overview: Neurocrine is a biopharmaceutical company focused on discovering and developing novel products for central nervous and immune system disorders. The company has not generated product sales revenue and relies on strategic alliances and collaborative research agreements for funding. As of September 30, 1996, the company had an accumulated deficit of $14.5 million.

Key Financial Metrics

Liquidity Note: Total liquid assets (cash, equivalents, and short-term investments) totaled approximately $60.6 million. This excludes $9.2 million held by the Canadian subsidiary (NPI) and $4.5 million receivable from collaborators.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased significantly to $2.2 million for the quarter and $9.9 million for the nine-month period, compared to $0.8 million and $5.2 million in the same 1995 periods. This was driven by increased sponsored research and milestone revenues, particularly from the Ciba-Geigy collaboration.
• Profitability Shift: The company reported a net loss of $405,000 for the quarter but achieved net income of $1.4 million for the nine-month period, reversing a $1.7 million loss in the prior year's nine-month period.
• Expense Increases: Research and development expenses rose to $3.0 million (quarter) and $8.3 million (nine months) due to expanded scientific personnel and activities in CRF and Altered Peptide Ligand programs.
• Capital Structure: Following a May 1996 Initial Public Offering (IPO) and concurrent sales to corporate partners, the company raised significant capital, resulting in a substantial increase in cash and short-term investments compared to December 31, 1995.

Outlook, Risks, and Management Commentary

• Strategic Alliances:
  • Janssen Pharmaceutica: Agreement for CRF receptor antagonists; $5.3 million paid to date with potential for additional payments and milestones up to $19 million.
  • Ciba-Geigy: Agreement for altered peptide ligands; obligated to provide $12.0 million in the first two years with potential for further funding and milestones.
  • Eli Lilly (Subsequent Event): In October 1996, entered a new agreement for CRF-binding protein ligand inhibitors with an estimated total value of up to $74.0 million, including $22.0 million in guaranteed fees.
• Liquidity Outlook: Management believes existing capital resources, interest income, and future collaboration payments will satisfy funding requirements through at least 1998.
• Risks:
  • Dependence on corporate partners for funding, compound selection, clinical trials, and commercialization.
  • Uncertainty regarding regulatory approvals and clinical trial success.
  • Potential termination of strategic alliances by partners.
  • Need for additional funding if current resources are insufficient.

Investor Verification Checklist

• Revenue Recognition: Verify the timing and criteria for recognizing milestone and license fee revenues under the Janssen and Ciba-Geigy agreements.
• Subsequent Event Impact: Assess the financial impact and terms of the October 1996 Eli Lilly agreement, which was signed after the reporting period.
• Subsidiary Status: Confirm the non-consolidated status of Neuroscience Pharma (NPI) Inc. and the availability of its $9.4 million in assets for Neurocrine's programs.
• Burn Rate: Monitor the rate of cash consumption in operating activities ($3.3 million used in nine months) against the projected runway through 1998.
• Dilution: Review the impact of stock option grants and potential future equity issuances on earnings per share.